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A B S T R A C T
Background
Discoid lupus erythematosus (DLE) is a chronic form of cutaneous lupus, which can cause scarring. Many drugs have been used to
treat this disease and some (such as thalidomide, cyclophosphamide and azathioprine) are potentially toxic. This is an update of a
Cochrane Review first published in 2000, and previously updated in 2009. We wanted to update the review to assess whether any
new information was available to treat DLE, as we were still unsure of the effectiveness of available drugs and how to select the most
appropriate treatment for an individual with DLE.
Objectives
To assess the effects of drugs for discoid lupus erythematosus.
Search methods
We updated our searches of the following databases to 22 September 2016: the Cochrane Skin Specialised Register, CENTRAL,
MEDLINE, Embase and LILACS. We also searched five trials databases, and checked the reference lists of included studies for further
references to relevant trials. Index Medicus (1956 to 1966) was handsearched and we approached authors for information about
unpublished trials.
Selection criteria
We included all randomised controlled trials (RCTs) of drugs to treat people with DLE in any population group and of either gender.
Comparisons included any drug used for DLE against either another drug or against placebo cream. We excluded laser treatment,
surgery, phototherapy, other forms of physical therapy, and photoprotection as we did not consider them drug treatments.
Data collection and analysis
At least two reviewers independently extracted data onto a data extraction sheet, resolving disagreements by discussion. We used standard
methods to assess risk of bias, as expected by Cochrane.
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Main results
Five trials involving 197 participants were included. Three new trials were included in this update. None of the five trials were of high
quality.
’Risk of bias’ assessments identified potential sources of bias in each study. One study used an inappropriate randomisation method,
and incomplete outcome data were a concern in another as 15 people did not complete the trial. We found most of the trials to be at
low risk in terms of blinding, but three of the five did not describe allocation concealment.
The included trials inadequately addressed the primary outcome measures of this review (percentage with complete resolution of skin
lesions, percentage with clearing of erythema in at least 50% of lesions, and improvement in patient satisfaction/quality of lifemeasures).
One study of fluocinonide cream 0.05% (potent steroid) compared with hydrocortisone cream 1% (low-potency steroid) in 78 people
reported complete resolution of skin lesions in 27% (10/37) of participants in the fluocinonide cream group and in 10% (4/41) in the
hydrocortisone group, giving a 17% absolute benefit in favour of fluocinonide (risk ratio (RR) 2.77, 95% CI 0.95 to 8.08, 1 study, n
= 78, low-quality evidence). The other primary outcome measures were not reported. Adverse events did not require discontinuation
of the drug. Skin irritation occurred in three people using hydrocortisone, and one person developed acne. Burning occurred in two
people using fluocinonide (moderate-quality evidence).
A comparative trial of two oral agents, acitretin (50 mg daily) and hydroxychloroquine (400 mg daily), reported two of the outcomes of
interest: complete resolution was seen in 13 of 28 participants (46%) on acitretin and 15 of 30 participants (50%) on hydoxychloroquine
(RR 0.93, 95% CI 0.54 to 1.59, 1 study, n = 58, low-quality evidence). Clearing of erythema in at least 50% of lesions was reported in
10 of 24 participants (42%) on acitretin and 17 of 25 (68%) on hydroxychloroquine (RR 0.61, 95% CI 0.36 to 1.06, 1 study, n = 49,
low-quality evidence). This comparison did not assess improvement in patient satisfaction/quality of life measures. Participants taking
acitretin showed a small increase in serum triglyceride, not sufficient to require withdrawal of the drug. The main adverse effects were
dry lips (93% of the acitretin group and 20% of the hydroxychloroquine group) and gastrointestinal disturbance (11% of the acitretin
group and 17% of the hydroxychloroquine group). Four participants on acitretin withdrew due to gastrointestinal events or dry lips
(moderate-quality evidence).
One trial randomised 10 people with DLE to apply a calcineurin inhibitor, pimecrolimus 1% cream, or a potent steroid, betamethasone
17-valerate 0.1% cream, for eight weeks. The study reported none of the primary outcome measures, nor did it present data on adverse
events.
A trial of calcineurin inhibitors compared tacrolimus cream 0.1% with placebo (vehicle) over 12 weeks in 14 people, but reported none
of our primary outcome measures. In the tacrolimus group, five participants complained of slight burning and itching, and for one
participant, a herpes simplex infection was reactivated (moderate-quality evidence).
Topical R-salbutamol 0.5% cream was compared with placebo (vehicle) over eight weeks in one trial of 37 people with DLE. There
was a significant improvement in pain and itch in the salbutamol group at two, four, six, and eight weeks compared to placebo, but the
trial did not record a formal measure of quality of life. None of the primary outcome measures were reported. Changes in erythema did
not show benefit of salbutamol over placebo, but we could not obtain from the trial report the number of participants with clearing
of erythema in at least 50% of lesions. There were 15 events in the placebo group (experienced by 12 participants) and 24 in the
salbutamol group (experienced by nine participants). None of the adverse events were considered serious (moderate-quality evidence).
Authors’ conclusions
Fluocinonide cream may be more effective than hydrocortisone in clearing DLE skin lesions. Hydroxychloroquine and acitretin appear
to be of equal efficacy in terms of complete resolution, although adverse effects might be more frequent with acitretin, and clearing
of erythema in at least 50% of lesions occurred less often in participants applying acitretin. Moderate-quality evidence found adverse
events were minor on the whole. There is not enough reliable evidence about other drugs used to treat DLE. Overall, the quality of the
trials and levels of uncertainty were such that there is a need for further trials of sufficient duration comparing, in particular, topical
steroids with other agents.
P L A I N L A N G U A G E S U M M A R Y
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Discoid lupus erythematosus (DLE) is a form of skin inflammation which occurs particularly on sun-exposed skin and can cause
scarring. All forms of cutaneous lupus erythematosus are most common in women of childbearing age, which is important because
some treatments, including thalidomide and acitretin, can cause birth defects, and hydroxychloroquine may cause damage to the eye
or ear. As the chronic nature and scarring of DLE can have psychological impact, and some treatments may produce serious adverse
effects, we felt it was important to combat uncertainty and identify the best and safest treatment. The evidence is current to September
2016.
Review question
We aimed to identify the best treatment for people with DLE, to reduce the risk of scarring and possible psychological effects. We
searched for all possible drug treatments, including topical agents (steroids and pimecrolimus or tacrolimus) and oral agents, such as
hydroxychloroquine, retinoids, methotrexate, azathioprine, lenalidomide, and biological agents. Potentially, any of these interventions
could have been compared with placebo or with any other intervention. We excluded surgery, laser, photoprotection, phototherapy,
and other forms of physical therapy as we did not consider them drug treatments. We hoped to find evidence for effective treatment,
without serious adverse effects.
Study characteristics
We identified five studies, involving 197 people (aged between 17 and 82). Participants were recruited from Europe, Scandinavia, Iran,
and the United States. Most of the skin lesions were recorded on the face, ear, and scalp. The duration of disease ranged from one
month to 16 years. Treatments included steroid creams of different potencies (fluocinonide and betamethasone cream, both potent
steroids; and hydrocortisone, a low-potency steroid); oral hydroxychloroquine; oral acitretin; tacrolimus cream; pimecrolimus cream;
and salbutamol cream. The tacrolimus and salbutamol trials used placebo in the control arm.
Key results
In a trial involving 78 participants, fluocinonide cream 0.05% appeared nearly three times as effective as hydrocortisone cream 1% in
terms of complete clearing of the DLE (27% versus 10%). The percentage of people who had a reduction in the redness of at least
50% of their sores was not reported, nor was patient satisfaction. Skin irritation occurred in three people using hydrocortisone and one
person developed acne; burning occurred in two people using fluocinonide. Adverse events did not stop any participants continuing
to apply the creams.
Hydroxychloroquine 400 mg and acitretin 50 mg appear to work equally well in terms of complete resolution (50% versus 46%,
respectively).Marked improvement in redness may be less in the acitretin group (42% versus 68%), but neither drug has been compared
with placebo. Patient satisfaction was not measured. Adverse events, more common in the acitretin group, were reported as minor,
although four people stopped treatment due to dry lips and gastrointestinal symptoms.
Pimecrolimus cream 1% (an anti-inflammatory cream) was compared with betamethasone (steroid) 0.1% cream in a small 8-week
study involving 10 people, but none of the review primary outcomes were reported; nor were adverse effects.
A longer study using a similar type of cream, tacrolimus 0.1%, compared with placebo did not report the primary outcomes. Slight
burning and itching was reported in five participants applying tacrolimus, and a herpes simplex infection came back in one participant.
A few people reported burning or irritation after the use of tacrolimus cream, but not sufficient to cause withdrawal.
R-salbutamol 0.5% topical cream was compared with placebo cream in a trial of 37 people, but the primary outcomes of this review
were not reported. There were only minor adverse events reported in each group: 15 in the placebo group and 24 in the salbutamol
group.
Quality of the evidence
For our primary outcome of clearing or excellent improvement, we had low-quality evidence for fluocinonide 0.05% compared with
hydrocortisone 1% as the only study assessing this comparison contained a high number of dropouts; while for acitretin (50 mg)
compared with hydroxychloroquine (400 mg), for our primary outcomes of reduction in erythema and complete resolution we rated
the quality of evidence as low, as the study contained a small number of people and differences between the groups in the number of
people who had forms of lupus other than DLE. Overall, moderate-quality evidence was found for adverse events.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Fluocinonide 0.05% compared with hydrocortisone 1% for discoid lupus erythematosus
Patient or population: people with discoid lupus erythematosus
Settings: not stated
Intervention: f luocinonide
Comparison: hydrocort isone
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
hydrocortisone fluocinonide
Clearing or excellent
improvement
(af ter 6 weeks of treat-
ment)
10 per 100 27 per 100
(9 to 79)
2.77 (0.95 to 8.08) 78
(1 study)
Low1 -
At least 50% reduct ion
in erythema
see comment see comment see comment see comment see comment This outcome was not
assessed.
Quality of lif e measure see comment see comment see comment see comment see comment This outcome was not
assessed.
Relapse see comment see comment see comment see comment see comment This outcome was not
assessed.
Adverse events of med-
icat ion, leading to dis-
cont inuat ion or signif i-
cant morbidity
see comment see comment see comment 78
(1 study)
Moderate2 The number of adverse
events in this study
was small and results
were presented narra-
t ively. For hydrocort i-
sone, 1 person devel-
oped acne and 3 ex-
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perienced irritat ion. 2
pat ients who were as-
signed to f luocinon-
ide experienced burning.
There was no discont in-
uat ion in either group
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk Ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
The assumed risk was the mean risk for the study populat ion
1Downgraded by two levels due to imprecision and high risk of bias (incomplete outcome data).
2Downgraded by one level for imprecision (small sample size).
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B A C K G R O U N D
Description of the condition
Discoid lupus erythematosus (DLE) is a chronic and common
formof cutaneous lupus - a formof skin inflammation of unknown
cause. It occurs particularly on sun-exposed skin, such as the face,
ears, and scalp, but occasionally is much more extensive, involving
large areas of skin. Some people with DLE have associated disease
in other parts of the body, but the majority of people with DLE
are otherwise healthy. People with DLE are seen frequently in skin
clinics throughout the world.
There have been no accurate studies of the prevalence of DLE, al-
though all forms of lupus erythematosus are particularly common
in women of childbearing age. The diagnosis of DLE is usually
made easily on clinical grounds, characteristic clinical findings be-
ing erythema (redness), follicular plugging (blocked and enlarged
openings to hair follicles), pigmentary disturbances, telangiectasia
(dilated capillaries), and atrophy (skin thinning). When the diag-
nosis is in doubt, a skin biopsy (microscopic examination) may be
required to confirm the diagnosis (Kuhn 2014).
In an attempt to improve consistency in the reporting of clinical tri-
als, the CLASI (Cutaneous Lupus Erythematosus Area and Sever-
ity Index) scoring systemhas been developed (Albrecht 2005). The
CLASI allows assessment of both active inflammation (erythema,
scale, and hypertrophy) and damage (dyspigmentation, scarring,
atrophy), in different body areas, but does not include a quality of
life score. It has not been tested in different populations.
Early effective treatment may lead to total clearing of the skin le-
sions, but failure of treatment results in permanent scarring. The
depressed scars, hair loss, and pigmentary changes are often ex-
tremely disfiguring, particularly in darker-skinned people. Perma-
nent scarring is the rule if treatment is delayed or inadequate.
Great emotional distress, social isolation, and difficulty obtaining
work are problems frequently suffered by these patients. Involve-
ment of the skin of the fingers and toes may markedly impair hand
function and limit walking (Vasquez 2013). In addition, people
with DLE are at risk of developing squamous cell carcinoma in
the scarred areas (Fernandes 2015).
Description of the intervention
The anti-malarial drug chloroquine is the traditional therapy for
DLE (Goldman 1953; Brodthagen 1959; Callen 1982). It is cheap
and readily available worldwide. Flare-ups of systemic lupus were
noted to occur with increased frequency after chloroquine was
stopped (Rothfield 1963). However, some people cannot tolerate
the drug and it is known to fail in others.Other anti-malarial agents
have been used, sometimes in combination with chloroquine, but
are not widely available (Kierland 1953; Maguire 1962; Feldman
1994).
In recent years, hydroxychloroquine has been used in place of
chloroquine in many countries, because ocular side-effects were
reported to be less frequent with hydroxychloroquine, but reti-
nal toxicity has subsequently also been recognised with hydroxy-
chloroquine (Geamanu 2014). The efficacy of the two forms of
the drug is thought to be the same, but no trials exist to confirm
this in DLE (Kreuter 2009). In discussing the treatment of DLE
in 1961, Prakken commented that: “This [lack of evidence] is il-
lustrated by a survey of our literature on the treatment of chronic
lupus erythematosus. Although many papers agree on their re-
ports of favourable results, the value of our therapy remains doubt-
ful because the influence of the placebo effect and the publica-
tions effect has not been eliminated” (Prakken 1961). However,
Rees felt that discoid lupus responded so dramatically to chloro-
quine that “double-blind studies are not required” (Rees 1963).
In 1964, Kraak performed a literature search and concluded that
available information was insufficient to evaluate the many ther-
apies that are recommended: “The literature leaves room for the
alarming assumption that none of the drugs might do any good”
(Kraak 1964). His group performed a non-randomised double-
blind trial comparing hydroxychloroquine with placebo (Kraak
1965). Spontaneous improvement or clearing occurred in some
of their patients, particularly in the winter months (Kraak 1965).
The group on chloroquine showed a greater tendency to improve
(Kraak 1965). Other workers have been so concerned about pos-
sible ocular side-effects (thought to be very rare on current low
dosage regimens) that chloroquine was excluded from their trial
(Mackey 1974). Smoking may reduce the efficacy of chloroquine
in people with lupus: a recent review reports studies that demon-
strate an inverse relationship between number of cigarettes smoked
and chloroquine blood levels (Chasset 2015). Unfortunatelymany
of the other agents, reported anecdotally to be of value in discoid
lupus erythematosus, have considerable potential side-effects and
some, such as thalidomide, may produce major malformations in
the foetus if taken during pregnancy (Cortés-Hernández 2012;
Zhou 2013).
Many other agents have been used to treat this condition (Callen
1997). Sunscreens and sun avoidance reduce flares of cutaneous
lupus, but are not usually sufficient alone (Kuhn 2011a). Other
possible treatments include dapsone (Coburn 1982; Lindskov
1986), topical and intralesional steroids (please note that the term
’steroid’ has been used in this review in place of the term ’corti-
costeroid’, although both terms have the same meaning) (Jansen
1965; Marsden 1968; Reyman 1974; Smith 1986), gold (Dalziel
1986), clofazimine (Mackey 1974), retinoids (Ruzicka 1988;
Shornick 1991), methotrexate (Goldstein 1994), azathioprine
(Tsokos 1985), lenalidomide (Okon 2014), thalidomide (Hasper
1983; Knop 1983; Naafs 1985), topical salbutamol (Jemec 2009),
sulphasalazine (Artuz 1996), phenytoin (Rodriguez-Castellanos
1995), interferon alpha-2a (Martinez 1992), topical calcineurin
blockers (pimecrolimus and tacrolimus) (Wollina 2007; Tsellos
2008), and biological agents such as abatacept (Merrill 2010a),
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belimumab (Manzi 2012), efalizumab (Usmani 2007), etanercept,
infliximab, rituximab, sifalimumab (Merrill 2011) and sirukumab
(Szepietowski 2013)
How the intervention might work
Steroids have anti-inflammatory and immunosuppressive effects,
acting on genetic material in the cell nucleus, via steroid receptors
in the cell (Norris 2005). Tacrolimus and pimecrolimus, which
are calcineurin inhibitors, inhibit the activity of T lymphocytes
(via calcium channels), a key cell in the development of cutaneous
lupus (Khandpur 2004). Salbutamol may exert an anti-inflamma-
tory effect by activating receptors on the surface of cells, particu-
larly lymphocytes and eosinophils (Jemec2009). Evidence suggests
that chloroquine and hydroxychloroquine which are antimalarials,
have an effect on inflammation by reducing antigen presentation
and the production of inflammatory cytokines (Rainsford 2015).
The anti-inflammatory mechanism of action of retinoids, such as
acitretin, are not fully understood. Retinoid receptors allow ac-
cess to the cell nucleus, and retinoids promote normal cell growth
(Schroeder 2007).
Why it is important to do this review
Permanent scarring is likely if treatment is delayed or inadequate.
People with DLE often experience great emotional distress. So-
cial isolation and difficulty obtaining work are frequent problems.
The relative efficacies of possible forms of treatment compared to
placebo or each other need to be clearly established. Some of these
agents (such as the cytotoxics) are potentially toxic (Weinblatt
2013; Goldberg 2015). Both thalidomide and the retinoids are
highly teratogenic (they may cause birth defects when given to
pregnant women), which renders their use in fertile women prob-
lematic (Ortiz 2013; Zhou 2013). It is this combination of un-
certainty of relative effectiveness and some potential to cause con-
siderable harm that has fuelled the need for this systematic review.
This is an update of a Cochrane Review first published in 2000
(Jessop 2000); and previously updated in 2009 (Jessop 2009).
O B J E C T I V E S
To assess the effects of drugs for discoid lupus erythematosus.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials of drug therapy for discoid lupus
erythematosus.
Types of participants
Participants at least 18 years of age.
A clinical diagnosis of discoid lupus erythematosus was accepted,
with or without histological confirmation. Studies that enrolled
people with different types of cutaneous lupus were included if
the subgroup with DLE could be identified separately.
Types of interventions
Any drug treatment aimed at clearing or improving the lesions of
DLE. This included:
• chloroquine, hydroxychloroquine, and other anti-malarial
quinines;
• thalidomide and lenalidomide;
• steroids, topical and systemic;
• retinoids, including acitretin, etretinate, isotretinoin;
• azathioprine;
• methotrexate;
• dapsone;
• clofazimine;
• phenytoin;
• gold;
• sulphasalazine;
• interferon alpha-2a;
• biological agents, including abatacept, adalimumab,
belimumab, etanercept, efalizumab, infliximab, rituximab,
sifalimumab and sirukumab;
• topical calcineurin antagonists, including tacrolimus,
pimecrolimus;
• topical salbutamol.
Potentially, any of these interventions could have been compared
with placebo or with any other intervention. Delivery of the drug
could be topical, parenteral or oral.
We excluded surgery, laser, photoprotection, phototherapy, and
other forms of physical therapy as we did not consider them drug
treatments.
Types of outcome measures
Primary outcomes
• Percentage of people with complete resolution of skin
lesions (i.e. return to normal skin appearance).
• Percentage of people with clearing of erythema in at least
50% of lesions (post-inflammatory pigmentation could persist).
• Improvement in patient satisfaction/quality of life measures.
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Secondary outcomes
• Relapse rate when medication stopped or reduced.
• Prevention of new lesions.
• Adverse effects of medication, leading to discontinuation or
significant morbidity.
• Implications for health care costs.
Search methods for identification of studies
We aimed to identify all relevant RCTs regardless of language
or publication status (published, unpublished, in press, or in
progress).
Electronic searches
For this update, we revised the search strategies for CENTRAL,
MEDLINE and Embase in line with current Cochrane Skin prac-
tices, and we re-ran our existing searches for the other databases.
Details of the previous search strategies are available in Jessop 2000
and Jessop 2009.
We searched the following up to 22 September 2016.
• Cochrane Skin Specialised Register using the following
terms: ((discoid and lupus) or (cutaneous and lupus)) and
erythematosus.
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2016, Issue 8) in the Cochrane Library using the
search strategy in Appendix 2.
• MEDLINE Ovid (from 1946) using the strategy in
Appendix 3.
• Embase Ovid (from 1974) using the strategy in Appendix 4.
• LILACS (Latin American and Caribbean Health Science
Information database, from 1982) using the strategy in
Appendix 5.
Trials Registries and Portals
We searched the following trials registries and portals to 20
September 2016 using the following search terms.
1. Discoid lupus erythematosus.
2. Skin lupus erythematosus.
3. Cutaneous lupus erythematosus.
• ISRCTN registry (www.controlled-trials.com).
• US National Institutes of Health Ongoing Trials Register (
www.clinicaltrials.gov).
• Australian New Zealand Clinical Trials Registry (
www.anzctr.org.au).
• World Health Organization International Clinical Trials
Registry platform (www.who.int/trialsearch).
• EU Clinical Trials Register (www.clinicaltrialsregister.eu).
Searching other resources
Handsearching
We hand searched Index Medicus for studies relating to treatment
of discoid lupus erythematosus for the years 1956 to 1966.
References from published studies
We checked the bibliographies of included studies for further ref-
erences to relevant trials.
Correspondence
We approached seven experts in the field of DLE treatment in an
attempt to identify other relevant studies, including unpublished
trials and dissertations. We asked three pharmaceutical companies
for records of unpublished trials.
We approached authors of registered but unpublished trials re-
questing their results.
Adverse effects
We did not perform a separate search for adverse effects of the
target intervention. However, we recorded all adverse events in
Characteristics of included studies and and Characteristics of
excluded studies.
Data collection and analysis
SJ and DW, with PJ’s assistance, extracted the data independently
and resolved differences by discussion.
MG examined and described the statistical information in indi-
vidual trials and edited or wrote the sections on measures of treat-
ment effect, data synthesis and unit of analysis issues and created
the ’Summary of findings’ tables.
Selection of studies
We (SJ, DW, PJ) screened the titles and abstracts and indepen-
dently selected them for inclusion or exclusion. We resolved dis-
agreements by discussion.
Data extraction and management
We (SJ, DW) extracted trial characteristics and outcomes, inde-
pendently, and recorded the data on a data extraction sheet. We
resolved disagreements by discussion.
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Assessment of risk of bias in included studies
We (SJ, DW, MG) assessed the risk of bias and the methodologi-
cal quality of included studies independently, using the following
components of internal and external validity for each included
study, as outlined in the Cochrane Handbook of Systematic Reviews
of Interventions (Higgins 2011).
a) The method of generation of the randomisation sequence.
b) The method of allocation concealment.
c) Who was blinded and not blinded.
d) The number of participants lost to follow-up and the reasons
provided for these losses.
e) Whether outcomes were analysed according to the intention-
to-treat principle.
f ) Comparability of the two treatment groups in each arm.
MG checked assessments in case of discrepancy.
Measures of treatment effect
For dichotomous outcomes (primary outcomes 1 and 2 and ad-
verse events), results are presented as risk ratios (RR) with 95%
confidence intervals (CI). Where the first treatment in the com-
parison is beneficial (RR > 1 for efficacy outcomes), we presented
the number needed to treat for an additional beneficial outcome
(NNTB) for any significant outcomes (P < 0.05). We planned
to present the number needed to treat for an additional harmful
outcome (NNTH) where the first treatment in the comparison is
harmful (RR > 1 for safety outcomes) for any significant adverse
outcomes (P < 0.05).
Where results were estimated for individual studies with low num-
bers of outcomes (< 10 in total) or where the total sample size were
less than 30 participants, we planned to report the proportion of
outcomes in each treatment group, together with a P value from
a Fisher’s Exact test (obtained using the “tabi” calculator in Stata
version 14).
For continuous outcomes (primary outcome 3), we planned to
present results in the form of mean differences (with 95% CIs).
Where there were treatment comparisons where studies used dif-
ferent scales for the same outcome, we planned to convert results
to standard mean differences (SMD) to allow pooling of results.
Unit of analysis issues
Cross-over trials
We followed the guidance provided in Section 16.4.4 of the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011). Where no evidence of a carry-over effect was present, anal-
yses of paired differences were presented if these data could be
obtained from the trial report. Otherwise, only data from the first
treatment period were used.
Within-patient studies
Internally controlled trials were analysed using techniques for
paired designs (e.g. paired t-test, McNemar’s test). Where appro-
priate, these were included in additional data tables and not pooled
with parallel group trials.
Dealing with missing data
The use of ’intention-to-treat’ analysis was reported in the ’Risk
of bias’ tables of the ’Characteristics of included studies’ tables. SJ
wrote to five authors and received a response from three authors;
some of the investigators in trial registries did not supply contact
details.
Assessment of heterogeneity
We planned to test statistical heterogeneity using the I² statistic
(0% to 40%: may not be important; 30% to 60%: may represent
moderate heterogeneity; 50% to 90%: may represent substantial
heterogeneity; 75% to 100%: represents considerable heterogene-
ity) (Higgins 2011),However, assessment of heterogeneity was not
performed as no findings were based on pooled results from two
or more trials. If in future updates meta-analyses are performed,
the heterogeneity will be quantified using the I² statistic. In cases
of substantial heterogeneity (I² > 80%), studies will not be pooled
and instead reasons for heterogeneity will be explored.
Assessment of reporting biases
Assessment for reporting biaswas not possible in the present review
as this contained no pooled results from meta-analyses.
If in future updates of this review there are 10 studies or more
of any single intervention, funnel plots will be used to evaluate
asymmetry, using Egger’s method (Egger 1997), as described in
section 10.4.3.1 of theCochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011). A degree of reporting bias was
identified in Jemec 2009, with details of erythema not reported,
although this was described as part of the outcome score. Differ-
ence in erythema was not statistically significant.
Data synthesis
We planned to draw up a synthesis of included trials; however,
this was not possible with the data in the studies we found, due to
heterogeneity of study methods and interventions. No two trials
investigated the same interventions. If in future updates of the
review it is possible to pool results then we will use random effects
meta-analysis for both dichotomous and continuous outcomes to
account for the anticipated heterogeneity between studies.
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Subgroup analysis and investigation of heterogeneity
In the protocol, we had planned to perform subgroup analysis on
the following measures: disseminated DLE versus localised DLE;
DLE with systemic lupus versus DLE without systemic lupus;
histologically proven versus clinically diagnosed DLE; and effect
of ethnic group on outcome. However subgroup analysis was not
possible in this update.
Other
We planned where possible to calculate cost effectiveness ratios
using quality-of-life measures; however, the studies identified did
not provide these data.
Sensitivity analysis
Sensitivity analyses were not carried out as no findings from this
review were based on pooled results from two or more studies. If in
future updates of this review pooled results are presented, sensitiv-
ity analyses will be carried out restricting results to studies assessed
as being at low risk of bias for all of the following three domains:
allocation concealment; blinding of participants and outcomes as-
sessors; and incomplete outcome data (Higgins 2011).
’Summary of findings’ table
’Summary of findings’ tables as detailed in theCochrane Handbook
for Systematic Reviews of Interventions were produced from within
ReviewManager 5 (RevMan 5) software (Higgins 2011). In these,
we have summarised the primary outcomes for the most impor-
tant comparisons (Summary of findings for the main comparison;
Summary of findings 2; Summary of findings 3; Summary of
findings 4; Summary of findings 5). Confidence intervals for the
corresponding risk were calculated using GRADEpro 2008 soft-
ware.
R E S U L T S
Description of studies
Results of the search
We retrieved 71 records from the searches for the 2009 review
(Jessop 2009), of which twomet the criteria for inclusion (Roenigk
1980 and Ruzicka 1992). Literature searches in 2014, 2015, and
2016 yielded a further 155 studies. We identified 12 studies from
our searches of trials registers. In total we screened 238 records.
We excluded 202 records on the basis of titles and abstracts.
Of the remaining 36 records, one article was not available in
full text and has been added to studies awaiting classification
(Pothinamthong 2012) along with eight trials registry records (see
Characteristics of studies awaiting classification). One study is on-
going (see Characteristics of ongoing studies). The remaining 26
articles were assessed in full text for eligibility.
Of the 26 full texts, we excluded 23 studies (14 did not describe
outcomes in the DLE group specifically and others were excluded
because they referred to photoprotection trials and not drug trials
or were not RCTs) (see Characteristics of excluded studies). We
included three new studies in this update (Barikbin 2009, Jemec
2009, and Kuhn 2011), giving a total of five included studies
altogether (see Characteristics of included studies). We noted that
diagnosis of DLE was generally based on clinical judgement in the
early studies, but investigators required histological (skin biopsy)
confirmation in the three new studies.
Of the nine drug trials of DLE listed in Characteristics of
studies awaiting classification, the interventions included etaner-
cept, other biologics, R-salbutamol, pimecrolimus, and an oral
retinoid, alitretinoin. Half of the studies were described as com-
plete but results have not yet been published. We attempted to
contact two of the investigators, without success. One investigator
reported that their study did not include analysis of the subset
with DLE.
For a summary of our screening process see Figure 1.
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Figure 1. Study flow diagram
Included studies
We included five studies, three of which were new. The full details
are in the Characteristics of included studies table. There were a
total of 197 participants (see sample sizes).
Design
The first study, involving 78 people, was a double-blind RCT
comparing two steroid creams of different potencies (Roenigk
1980). The creams were prepared in the same cream base and
identical tubes, and were compared in a 12-week cross-over trial. A
single active lesion on each personwas chosen formonitoring.One
of the creams was applied for 6 weeks, then the other for a further
6 weeks. Only the outcome prior to cross-over was included in the
analysis for this review.
The second trial was a double-blind RCT, over 8 weeks (Ruzicka
1992).
The third trial, was a double-blind RCT, over 8 weeks (Barikbin
2009).
In Jemec 2009, an active agent was compared with placebo, in a
double-blind RCT. The creams were identical.
A 2011 trial was a double-blind placebo-controlled RCT, over 12
weeks (Kuhn 2011). The vehicle was used as the placebo, to ensure
blinding.
Sample sizes
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There were a total of 197 participants in the five trials: 78 in
Roenigk 1980; 58 in Ruzicka 1992; 10 in Barikbin 2009; 37 in
Jemec 2009; and 14 in the study by Kuhn 2011.
Setting
The setting of Roenigk 1980 was not stated. Ruzicka 1992,
Barikbin 2009, Jemec 2009 and Kuhn 2011 were set in specialised
lupus clinics, as most people with DLE were attending such clin-
ics.
Participants
Roenigk 1980 randomised for inclusion 32 men and 61 women,
aged 17 to 82 years, from the following ethnic groups: 23 black
American, and 25 white American in one group; and 23 black
American, and 22 white American in the other. The duration of
their disease was very variable (1 to 240 months). There were no
significant differences between people in the two arms, in terms of
demographics or duration of disease. All participants had chronic
DLE. However final number of participants was 78, (others ex-
cluded at onset) and ethnic and gender breakdown of participating
group was not supplied.
In Ruzicka 1992, there were 22 men and 36 women, with a mean
age of 43.3 years. The ethnic group was not mentioned. All par-
ticipants had cutaneous lupus, 39 discoid and 19 subacute LE.
People with subacute LE were more highly represented in the hy-
droxychloroquine arm.
In Barikbin 2009 , participants were Iranian, aged 20 to 53, and
7 of the 10 were women. Participants in Jemec 2009 included
28 women and 9 men, aged 34 to 72. There was no ethnicity
provided. In the Kuhn 2011 trial, there were six women and eight
men with DLE, with a mean age of 49.8 ± 5.9. Ethnicity was not
supplied.
Interventions
Roenigk 1980 compared two topical steroids, fluocinonide 0.05%
(potent steroid) and hydrocortisone 1% (mild steroid) in the same
cream base.
Ruzicka 1992 compared two oral agents, acitretin (a synthetic
retinoid) and hydroxychloroquine (an anti-malarial).
Barikbin 2009 compared pimecrolimus 1% cream with be-
tamethasone 17-valerate 0.1% cream.
Jemec 2009 compared salbutamol 0.5% creamwith placebo (same
vehicle, so indistinguishable).
Kuhn 2011 compared tacrolimus 0.1% cream with placebo (ve-
hicle).
Outcomes
In Roenigk 1980, the outcome was based on the authors’ own 5-
point scale, using a single test site. The investigators used a scale,
providing a score of 1 if the lesion became worse, 2 if there was no
improvement, 3 if there was a little improvement, 4 if improve-
ment was marked, and 5 if the lesion cleared or showed excellent
improvement. There was no assessment by the participants.
Assessment of severity in Ruzicka 1992 was based on an ordinal
scale using erythema (redness), infiltration (thickness), and scal-
ing with complete clearing graded as 0, improvement as 1, and
no change or deterioration as 2. Extent of skin disease and the
occurrence of adverse reactions were also documented.
Barikbin 2009 used digital photographs, which were examined by
three blinded dermatologists, using a severity score.
Jemec 2009 reported outcomes using the CLASI score, the clini-
cian’s global assessment and the participant’s global assessment.
Kuhn 2011 used digital photography and a clinical assessment,
using a clinical score. They reported adverse events.
Quality-of-life measures or participant global evaluation were not
recorded in any of the studies.
Excluded studies
Details of the 23 excluded studies can be found in the
Characteristics of excluded studies table. In 14 studies, partici-
pants had systemic or cutaneous lupus, or both, but the group
with DLE were not described specifically, so the influence of treat-
ment in DLE could not be established. Seven trials were not ran-
domised. Authors of two excluded RCTs reported results with
topical tacrolimus versus topical clobetasol propionate, and clo-
fazimine versus chloroquine diphosphate (Bezerra 2005; Tzung
2007). However, in both studies participants had various forms
of cutaneous lupus and results for individual subsets were not re-
ported separately, thus it was not possible to establish the relative
benefits of individual treatments in DLE. Avgerinou 2012 was not
an RCT and the DLE subset was not reported. Gammon 2011
did not report results for the DLE subset. Manzi 2012, Merrill
2010a, Merrill 2010b, Merrill 2011 and Szepietowski 2013 de-
scribed people with SLE and did not provide data for theDLE sub-
set. The study of mucosal DLE, comparing tacrolimus ointment
and triamcinolone cream by Wang 2015 had major methodology
flaws: participants were not blinded and the basis for diagnosis of
DLE was not clear (Wang 2015).
We found 12 registered trials in the trial registries. We attempted
to contact investigators where the trial was described as completed
and had not been published, but very few trial records provided
relevant contact details. We received two replies, confirming that
people with DLE had not been recorded separately in their trials.
Risk of bias in included studies
Overall, risk of bias was considered low or unclear for most pa-
rameters for the included studies.
See Figure 2 for the risk of bias summary of the judgements for
each included study.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
The topical steroid study Roenigk 1980 was randomised and sta-
tistical tests for equality confirmed that randomisation was suc-
cessful; however, no mention was made of allocation concealment.
In Ruzicka 1992, comparing hydroxychloroquine and acitretin,
participants were randomised but methods taken to conceal the
allocation were not stated.
In Barikbin 2009, randomisation was applied by the use of odd
and even numbers, (quasi-randomisation), hence was considered
high risk of selection bias from an inadequate random sequence
generation. However, the method used would not introduce selec-
tion bias from allocation concealment as numbers were assigned
on the basis of order of referral, so decisions made (re: participa-
tion) could not have been made with knowledge of the treatment
to be received.
In Jemec 2009, randomisationwas generated from a randomnum-
ber list. However, details as to whether the randomisation list was
available to recruiting clinicians was not stated (unclear allocation
concealment).
In Kuhn 2011, random numbers were computer generated and
allocation was conducted by a pharmacist who was independent
of the study investigators (adequate concealment of allocation).
Blinding
IParticipant blinding was clearly stated in Roenigk 1980; however,
blinding of outcome assessors was not described (although the trial
was described as double blind). Ruzicka 1992 was described as
double-blind, but no details were provided.
Blinding was described in Barikbin 2009, with identical jars of test
agents. In Jemec 2009, blinding was described for both assessors
and participants. The Kuhn 2011 study similarly used identical
containers and both participants and assessors were blinded.
Incomplete outcome data
In the Roenigk 1980 study, data from 78 people were available
for analysis at the end of the first phase (six weeks). Fifteen people
dropped out during the first phase, 13 because of non-compliance,
and two because of the use of a proscribed drug. Hence, the study
was judged at high risk of attrition bias.
The remaining studies were at low risk of attrition bias. In Ruzicka
1992, 51 of 58 participants completed the trial (83%). Among
those given acitretin, four people dropped-out because of side-
effects (not detailed), another because of treatment failure, and a
sixth due to non-compliance. In the hydroxychloroquine group
three peoplewithdrew from the study prematurely because of com-
plete clearing of skin lesions and one because of failure of treat-
ment. Intention-to-treat analysis was used.
There were no withdrawals from the Barikbin 2009 trial.
In the Jemec 2009 study, the numbers contributing to the analyses
were not stated but it was clearly stated that an intention-to-treat
analysis was carried out.
In the Kuhn 2011 trial, two of the 14 participants with DLE did
not complete the trial. Intention to treat analysis was used in a
secondary analysis.
Overall, ITT analysis was described in three studies: Barikbin
2009, Jemec 2009, and Kuhn 2011. It was not reported in the
other two studies and this was a clear potential risk of bias in the
Roenigk 1980 trial, as 15 participants were excluded from final
analysis.
Selective reporting
One study was considered to be at high risk of selective reporting
because they authors did not provide details on the impact on
erythema (Jemec 2009). In two studies it was unclear if there
was selective reporting (Kuhn 2011, Roenigk 1980), while the
remaining two studies were judged as low risk (Barikbin 2009,
Roenigk 1980), as all expected outcomes were reported.
Other potential sources of bias
Overall, it was unclear whether studies were at risk of other po-
tential sources of bias, except for Ruzicka 1992 where high clini-
cal heterogeneity was identified; hence, was judged as high risk of
other bias. Studies were also assessed separately for ’Comparability
of the two arms’, see below.
Comparability of the two arms
The risk of bias was rated as low in four studies. In the Roenigk
1980 trial, the groups were comparable at baseline. The partici-
pants in the two arms in the Jemec 2009 study had similar active
lesions at baseline (activity scores 1.32 ± 0.48 vs 1.11 ± 0.47). The
mean disease severity score was similar between the two groups at
baseline in the Barikbin 2009 study. Kuhn 2011 also had compa-
rable arms at baseline.
Ruzicka 1992 included 19 people with subacute cutaneous lupus
erythematosus. As people with this form of cutaneous lupus were
more strongly represented in the chloroquine group, this might
have influenced the outcome of treatment, as people with suba-
cute lupus may have a better response rate. The response rates for
discoid lupus and subacute lupus were not described separately.
Hence, this study was judged to be at high risk of bias.
We are of the opinion that none of the five studies included in this
review are affected by other potential threats to validity, including:
• interim results analysis;
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• deviation from study protocol not reflecting clinical
practice;
• prerandomisation of the intervention which could affect the
result;
• contamination of drugs (pooling of drugs by participants);
• overly wide inclusion criteria for participants;
• use of insensitive instruments to measure outcomes;
• selective reporting of subgroups;
• inappropriate influence of funders.
Effects of interventions
See: Summary of findings for the main comparison
Fluocinonide 0.05% compared with hydrocortisone 1%;
Summary of findings 2 Acitretin 50 mg daily compared with
hydroxychloroquine 400 mg daily; Summary of findings 3
Pimecrolimus 1% compared with betamethasone 17-valerate
0.1%; Summary of findings 4 R-salbutamol 0.5% topical cream
comparedwith placebo;Summary of findings 5Tacrolimus 0.1%
cream compared with placebo
Primary outcomes
• Percentage of people with complete resolution of skin
lesions (i.e. return to normal skin appearance).
• Percentage of people with clearing of erythema in at least
50% of lesions (post-inflammatory pigmentation could persist).
• Improvement in patient satisfaction/quality-of-life
measures.
Percentage of people with complete resolution of skin
lesions (i.e. return to normal skin appearance)
Note that we accepted the following terms to describe complete
resolution: complete clearing, clearing, marked improvement and
excellent improvement.
In the Roenigk 1980 study fluocinonide 0.05% cream appeared
to be superior to hydrocortisone 1% cream (low-potency steroid)
in the treatment of discoid lupus erythematosus (Summary of
findings for themain comparison). At the 6-week cross-over point,
clearing or excellent improvement was found in 10 out of 37
people (27%) using fluocinonide and in four out of 41 people
(10%) using hydrocortisone (RR 2.77, 95% CI 0.95 to 8.08), 1
study, n = 78, low-quality evidence) (Analysis 1.1). This shows an
absolute benefit of potent steroid of 17% (95% CI 0 to 34%).
The quality of evidence for this outcome was judged to be low.
In the Ruzicka 1992 study, the overall outcome appeared similar
in the hydroxychloroquine 400 mg and acitretin 50 mg groups
(Summary of findings 2). There wasmarked improvement or com-
plete clearing in 13 out of 28 (46%) participants given acitretin
and in 15 out of 30 (50%) of those on hydroxychloroquine; i.e.
there was no significant difference between the two groups (RR
0.93, 95% CI 0.54 to 1.59) (Analysis 2.1).The quality of evidence
for this outcome was judged to be low.
In the Barikbin 2009 study, those treated with pimecrolimus 1%
had an 86% reduction in severity score compared to 73% in the
betamethasone 17-valerate 0.1% cream group (P = 0.1). The num-
ber of participants with complete resolution could not be obtained
from the paper (Summary of findings 3).
In the study by Jemec 2009, the number of participants with com-
plete resolution could not be obtained from the paper (Summary
of findings 4).
In the Kuhn 2011 study looking at tacrolimus 0.1% cream versus
placebo (vehicle), no participants with DLE were reported as hav-
ing experienced complete clearing (Summary of findings 5). The
quality of evidence for this outcome was judged to be low.
Percentage of people with clearing of erythema in at least
50% of lesions (postinflammatory pigmentation could
persist)
In none of the studies was there a measurement of the percentage
of participants with clearing of erythema in at least 50% of lesions.
Roenigk 1980 used a score that included erythema tomeasure out-
come, but did not report the erythema separately. In the Ruzicka
1992 study the effect on erythema was assessed using an ordinal
scale where complete clearing was graded as 0 and improvement
as 1, so we take this to mean there was clearing of erythema in
at least 50% of lesions. Erythema showed more marked improve-
ment in the hydroxychloroquine 400 mg group and more people
in this group showed complete clearing compared to those taking
acitretin 50mg, although the result was not statistically significant.
There was complete clearing or marked improvement of erythema
in 10/24 (42%) of participants in the acitretin group compared
to 17/25 (68%) in the hydroxychloroquine group (RR 0.61, 95%
CI 0.36 to 1.06) (Analysis 2.2.) The quality of evidence for this
outcome was judged to be low.
While Barikbin 2009 recorded erythema in treated sites as part of
the clinical score, results for erythemawere not reported separately.
In the Jemec 2009 study, there was no significant improvement in
erythema, but the actual data were not provided.
In the Kuhn 2011 study, erythema was included in the clinical
score, but actual data were not provided.
Improvement in participant satisfaction/quality of life
measures
There was no record of any measurements of participant satisfac-
tion or quality of life in any of the included studies. Jemec 2009
and Kuhn 2011 recorded itch and pain as reported by participants,
but no global score or assessment of quality of life.
Secondary outcomes
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• Relapse rate when medication stopped or reduced.
• Prevention of new lesions.
• Adverse effects of medication, leading to discontinuation or
significant morbidity.
• Implications for health care costs.
Relapse rate when medication stopped or reduced
There was no explicit record of relapse rates when medication was
stopped in three of the studies. Barikbin 2009 reported that there
was no relapse at eight weeks, after stopping the trial medication
at four weeks. The trial of Kuhn 2011 reported improvement
in skin lesions at four and eight weeks but the benefit was not
maintained at 12 weeks. Thus the skin condition had relapsed
while the participants were still using the trial cream, tacrolimus
0.1%.
Prevention of new lesions
In none of the studies was this outcome directly measured.
Adverse effects of medication, leading to discontinuation or
significant morbidity
In the Roenigk 1980 study, adverse effects were minor and were
seen in both groups (moderate-quality evidence). Skin irritation
occurred in three people using hydrocortisone cream 1% and
burning occurred in two people using fluocinonide cream 0.05%.
One person in the hydrocortisone group developed acne. The trial
was too short to assess other side-effects, such as skin atrophy
(thinning) or capillary damage.
In the Ruzicka 1992 study, compared with those taking hydrox-
ychloroquine 400 mg adverse effects were more frequent in the
acitretin group 50mg andweremore severe, with four participants
having to discontinue treatment because of adverse effects (mod-
erate-quality evidence). The main clinical adverse effects were dry
lips/cheilitis (93% of the acitretin and 20% of the hydroxychloro-
quine group) and gastrointestinal disturbance (11% of the ac-
itretin and 17% of the hydroxychloroquine group, but no specific
information was provided). Laboratory studies revealed changes in
triglycerides in both groups, the levels rising from a mean of 1.66
to 2.10 mmol/l in the acitretin group (P = 0.01) and falling from
1.94 to 1.50 mmol/l in the hydroxychloroquine group (P = 0.02).
The difference between the two groups was highly significant (P
= 0.006).
In the Barikbin 2009 study, adverse events were not reported.
In the Jemec 2009 trial there were 39 reported adverse events, 15
in the placebo group and 24 in the salbutamol 0.5% topical cream
group (moderate-quality evidence). None of the adverse events
were considered serious and the adverse events did not appear to
be related to the trial medication.
Kuhn 2011 reported that five people experienced itching or burn-
ing at the site of tacrolimus 0.1% cream application, sometimes
lasting up to six weeks, and one participant developed herpes sim-
plex infection of the lip during treatment (moderate-quality evi-
dence). There were no serious adverse events. No adverse events
were experienced by the participants using the placebo cream.
Implications for healthcare costs
There was no measurement of this outcome in any of the studies.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Acitretin 50 mg daily compared with hydroxychloroquine 400 mg daily for discoid lupus erythematosus
Patients or population: people with discoid lupus erythematosus
Settings: specialised lupus clinic
Intervention: acitret in
Comparison: hydroxychloroquine
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
hydroxychloroquine acitretin
Clearing or excellent
improvement
(af ter 8 weeks of treat-
ment)
50 per 100 46 per 100
(27 to 80)
0.93 (0.54 to 1.59) 58
(1 study)
Low1 -
At least 50% reduct ion
in erythema
(af ter 8 weeks of treat-
ment)
68 per 100 42 per 100
(25 to 72)
0.61 (0.36 to 1.06) 49
(1 study)
Low1 -
Quality of lif e measure see comment see comment see comment see comment see comment This outcome was not
assessed.
Relapse see comment see comment see comment see comment see comment This outcome was not
assessed.
Adverse events of med-
icat ion, leading to dis-
cont inuat ion or signif i-
cant morbidity
see comment see comment see comment 58
(1 study)
Moderate2 Information on ad-
verse events was pre-
sented narrat ively. 27
out of 28 part icipants
receiving acitret in had
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at least one adverse
event compared with
17 out of 30 pat ients
treated with hydrox-
ychloroquine. 4 peo-
ple receiving acitret in
discont inued treatment
due to dry lips and gas-
trointest inal symptoms
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk Ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
The assumed risk was the mean risk for the study populat ion.
1Downgraded by two levels due to imprecision and high risk of bias (non-comparable treatment arms).
2Downgraded by one level for imprecision (small sample size).
1
8
D
ru
g
s
fo
r
d
isc
o
id
lu
p
u
s
e
r
y
th
e
m
a
to
su
s
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Pimecrolimus 1% compared with betamethasone 17-valerate 0.1% for discoid lupus erythematosus
Patients or population: people with discoid lupus erythematosus
Settings: dermatology clinics
Intervention: pimecrolimus
Comparison: betamethasone
Outcomes Illustrative comparative
risks* (95% CI)
Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Clearing or excellent im-
provement
(af ter 8 weeks of treatment)
see comment see comment 10
(1 study)
see comment There was a stat ist ically sig-
nif icant reduct ion in the dis-
ease severity score in both
treatment groups; however,
clearing or improvement was
not presented as a per-
centage and no comparat ive
analyses were performed
At least 50% reduct ion in
erythema
see comment see comment see comment see comment This outcome was not as-
sessed.
Quality of lif e measure see comment see comment see comment see comment This outcome was not as-
sessed.
Relapse see comment see comment see comment see comment This outcome was not as-
sessed.
Adverse events of medica-
t ion, leading to discont inua-
t ion or signif icant morbidity
see comment see comment see comment see comment This outcome was not as-
sessed.
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk Ratio
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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R-salbutamol 0.5% topical cream compared with placebo for discoid lupus erythematosus
Patient or population: people with discoid lupus erythematosus
Settings: dermatology departments
Intervention: R-salbutamol
Comparison: placebo
Outcomes Illustrative comparative
risks (95% CI)
Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Clearing or excellent im-
provement
see comment see comment 37
(1 study)
see comment While data on overall im-
provement were provided in
the study, the number of par-
t icipants with complete res-
olut ion in Jemec 2009 could
not be obtained f rom the trial
report .
At least 50% reduct ion in
erythema
see comment see comment 37
(1 study)
see comment While data on erythema were
provided in the study report ,
the number of part icipants
with at least 50% reduct ion
in erythema in Jemec 2009
could not be obtained f rom
the trial report .
Quality of lif e measure see comment see comment see comment see comment This outcome was not as-
sessed.
Relapse see comment see comment see comment see comment This outcome was not as-
sessed.
Adverse events of medica-
t ion, leading to discont inua-
t ion or signif icant morbidity
see comment see comment 37
(1 study)
Moderate1 Results for adverse events
were presented narrat ively.
There were 15 events in the
placebo group (experienced
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by 12 part icipants) and 24
in the salbutamol group (ex-
perienced by 9 part icipants)
. None of the adverse events
were considered serious
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk Ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Downgraded by one level for imprecision (small sample size).
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Tacrolimus 0.1% cream compared with placebo for discoid lupus erythematosus
Patient or population: people with discoid lupus erythematosus
Settings: dermatology departments
Intervention: tacrolimus
Comparison: placebo
Outcomes Illustrative comparative
risks (95% CI)
Illustrative comparative
risks (95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Clearing or excellent im-
provement
see comment see comment see comment see comment No part icipants with DLE in
either group in the study
by Kuhn 2011 experienced
complete clearing. Unable
to GRADE due to 0 events in
both groups
At least 50% reduct ion in
erythema
see comment see comment see comment see comment The results for erythema
in the study by Kuhn 2011
were not reported sepa-
rately.
Quality of lif e measure see comment see comment see comment see comment This outcome was not mea-
sured.
Relapse see comment see comment see comment see comment This outcome was not mea-
sured.
Adverse events of medica-
t ion, leading to discont inua-
t ion or signif icant morbidity
see comment see comment 14
(1 study)
Moderate1 Results for adverse events
were presented narrat ively.
In the tacrolimus group, 5
part icipants complained of
slight burning and itching,
and in 1 person a herpes
simplex infect ion was reac-
t ivated. There were no seri-
ous adverse events23
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Downgraded by one level for imprecision (small sample size).
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D I S C U S S I O N
Summary of main results
Five trials are reported in this version of the review, with a total
of 197 participants. Three of the studies are new to this update
(Barikbin 2009; Jemec 2009; Kuhn 2016). Two of the trials in-
cluded small numbers of participants (10 in Barikbin 2009 and
14 in Kuhn 2011).
Interventions in the five trialswere topical steroids, hydroxychloro-
quine, acitretin, topical salbutamol, topical tacrolimus, and topi-
cal pimecrolimus.
The study of topical steroids provides some evidence that a potent
steroid cream, fluocinonide 0.05%, may be superior to low-po-
tency hydrocortisone 1% in the complete resolution of discoid lu-
pus erythematosus skin lesions (Summary of findings for the main
comparison) (Roenigk 1980). The ideal duration of treatment or
likelihood of recurrences following treatment has not been estab-
lished. Our second primary outcome (percentage of people with
clearing of erythema in at least 50% of lesions) was not measured.
In the comparative trial of hydroxychloroquine 400 mg and ac-
itretin 50mg (Ruzicka 1992), no difference in efficacywas demon-
strated between the two drugs in terms of the primary outcome,
with complete resolution of skin lesions reported in 46% of peo-
ple taking acitretin and in 50% of those on hydroxychloroquine.
Regarding the second primary outcome, 42% of participants tak-
ing acitretin showed improvement in erythema in at least 50%
of lesions compared with 68% of the hydroxychloroquine group
(Summary of findings 2).
The two studies of calcineurin inhibitors (pimecrolimus 1% and
tacrolimus 0.1%) (Barikbin 2009; Kuhn 2011), and the study
of R-salbutamol 0.5% topical cream (Jemec 2009), unfortunately
included only 61 participants in all and did not report the primary
outcomes of the review (Summary of findings 3; Summary of
findings 4; Summary of findings 5).
There is some evidence that the trial drugs were free of serious
side-effects, but the short duration of most of the trials does not
allow any conclusion about long-term adverse effects of topical
steroids. Adverse events were reported in the 12-week tacrolimus
0.1% study, which was compared to placebo (Kuhn 2011), but
none were serious. Roenigk 1980 (fluocinonide cream 0.05% vs
hydrocortisone cream 1%) was short (six weeks in each arm), and
thus side-effects of long-term topical steroid use could not be as-
sessed. Ruzicka 1992 (acitretin 50 mg vs hydroxychloroquine 400
mg) was the only study that reported discontinuation of partic-
ipants due to adverse events (four people receiving acitretin dis-
continued treatment due to dry lips and gastrointestinal symp-
toms). Jemec 2009 compared topical salbutamol 0.5% creamwith
placebo (vehicle), and both groups reported minor adverse events
but no serious adverse events. Barikbin 2009 did not present data
on adverse events.
We are uncertain about the effect of the interventions on patient
satisfaction/quality of life, as this primary outcome was not mea-
sured by any of our included studies. The secondary outcomes of
preventing new lesions and implications for healthcare costs were
not assessed in any study either. Relapse rate when medication
was stopped or reduced was reported in Barikbin 2009 and Kuhn
2011. There was no relapse reported in Barikbin 2009 at eight
weeks, after stopping the trial medication at four weeks; whilst in
Kuhn 2011, participants relapsed by 12 weeks.
Overall completeness and applicability of
evidence
The studies in this review have not addressed all the objectives of
the review and do not identify the most effective treatment for
DLE in all types of participants.
The studies identified in this review did not address (or addressed
inadequately) the relative benefits of many currently used inter-
ventions, against each other or against placebo, including hy-
droxychloroquine (or chloroquine), retinoids, topical steroids, cal-
cineurin inhibitors, methotrexate, azathioprine, lenalidomide or
biological agents. Outcome measures failed to address quality of
life measures or, in most cases, relapse rate after medication was
stopped. Most studies did not report on complete resolution of
skin lesions or clearing of erythema either. Although different pop-
ulations participated in the trials, there were no trials from Asia,
Africa, Australia or South America.
Quality of the evidence
Five trials, involving 197 participants were included. Some pri-
mary outcomemeasures in this review (per cent with complete res-
olution, percentage with at least 50% improvement in erythema)
were inadequately addressed in themajority of included trials. Fur-
thermore, quality of life was not assessed in any of the five included
studies.
Where quantitative results were provided for primary outcomes,
the overall quality of the evidence was judged to be low owing
to the small size of most of the studies and high risk of bias on
important domains such as incomplete outcome data and non-
comparability of treatment arms at baseline.
All trials were judged to be at low risk of bias for blinding as they
were all double-blind and interventions were identical in appear-
ance (although for two studies, Roenigk 1980 and Ruzicka 1992,
the methods used to ensure blinding were not fully described). In
four studies the method used to generate the allocation sequence
was adequate; however, one study was a quasi-randomised trial
where patients were numbered based on time of referral and odd
numbered participants were allocated to one treatment and even
numbered patients to the other. However, as this study did not
include any of our pre-specified primary or secondary outcome
25Drugs for discoid lupus erythematosus (Review)
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measures (instead a total mean severity score was calculated before
and after treatment for each participant), no data for this study
were presented in our ’Summary of findings’ tables. The method
used to conceal allocation was also unclear in three of the studies
(Jemec 2009, Roenigk 1980; Ruzicka 1992); however, this was
judged to be adequate for the other two studies (Barikbin 2009;
Kuhn 2011), For four studies, either the numbers analysed were
the same as the number recruited or the number of dropouts was
very small, so these were judged to be at low risk of bias for incom-
plete outcome data. However in the Roenigk 1980 study, 15 of the
78 participants did not contribute data towards the primary out-
come of clearing or excellent improvement for reasons which may
relate to outcome (Summary of findings for themain comparison).
Therefore, the quality of evidence on whether there is a difference
between fluocinonide and hydrocortisone (low-potency steroid)
with respect to clearing or excellent improvementwas downgraded
by one level. In the trial by Ruzicka 1992, there were more par-
ticipants with DLE in the hydroxychloroquine group. This cre-
ated unbalanced treatment groups, which could have influenced
the outcomes of clearing or excellent improvement and more than
50% reduction in erythema (Summary of findings 2). We identi-
fied no other potential sources of bias that might have had a direct
effect on any risk measures presented, However, in many instances
our ability to assess these was unclear.
Sample size was judged to be inadequate in all of the included stud-
ies, except in the case of Roenigk 1980 with 78 participants (others
ranged from 10 to 58 participants per study). This resulted in im-
precise measures of effect in instances where these were presented,
and evidence was therefore downgraded accordingly in instances
where assessment of the quality of evidence is provided (Summary
of findings for themain comparison; Summary of findings 2). The
small numbers in Ruzicka 1992 may weaken the validity of this
study, as does the lack of a control arm, as neither intervention is
of established efficacy (Summary of findings 2). The inclusion of
people with subacute cutaneous lupus erythematosus is an even
greater source of possible error and the results require confirma-
tion.
We also assessed the quality of evidence for adverse events leading
to discontinuation or significant morbidity in four out of five
comparisons in the ’Summary of findings’ tables. The quality of
evidence was moderate, with downgrading for imprecision in all
comparisons because the evidence was based on only one study
with a small number of participants. Furthermore, only Ruzicka
1992 reported participants discontinuing, while the remaining
studies only reported minor adverse events. The overall sample
size may not have been large enough to identify serious adverse
events.
All of the comparisons included in this review were assessed in
single studies, which didnot allowus to assess consistency of results
across studies. As such it was not possible in our review to assess
what factors could potentially contribute to differences in findings
between studies (heterogeneity).
Indirectness cannot be assessed with confidence in the included
studies. As the studies were performed in specialist clinics andmost
people with DLE are likely to be treated initially at that level, the
setting is not out of line with clinical practice.
Potential biases in the review process
We attempted to conduct a comprehensive search for studies, but
the fact that one study has not yet been incorporated may be a
source of potential bias (Pothinamthong 2012). Studies in which
participants had SLE or undefined cutaneous LE were excluded
from the review, but two studies that included participants with
DLE and SCLE, (Ruzicka 1992 and Kuhn 2011), were included
and this may have introduced a bias. There were 12 studies iden-
tified in trials registries, but unpublished and most without con-
tact details. The reviewers were unable to establish the outcome
of these trials. After the publication of the original protocol and
review (Jessop 2000), a scoring measure was published, and has
been widely used for reporting outcomes in DLE (Albrecht 2005).
One included study (Jemec 2009) reported outcomes using this
scoring measure, but the data were not included in our systematic
review because this type of outcome measure was not specified in
the review protocol.
Agreements and disagreements with other
studies or reviews
We are not aware of any other relevant reviews or studies.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
1. There is currently insufficient evidence to guide clinicians
in the treatment of severe DLE.
2. Potent steroid cream (fluocinonide) appears to be more
effective than low-potency steroid cream (hydrocortisone) in the
treatment of discoid lupus erythematosus, although the potent
steroid was effective in only about a quarter of the people treated
and the low-potency steroid in about 10%.
3. Both hydroxychloroquine and acitretin are associated with
marked improvement or clearing in about half of all people
treated, but neither drug has been tested against placebo in a
randomised clinical trial.
4. At present there is no reliable evidence to support the use of
other specific treatments for discoid lupus erythematosus. This
should not be seen as evidence that current treatment is
ineffective but rather that evidence of effectiveness is lacking.
26Drugs for discoid lupus erythematosus (Review)
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Notably, there have been several large multicentre trials of newer
biological agents (Manzi 2012, Merrill 2010a, Merrill 2011,
Merrill 2010b, Szepietowski 2013), but unfortunately cutaneous
subsets have not been reported separately, so we cannot reach any
conclusion about possible benefits of biological agents in DLE.
Trials investigating the use of topical biological agents have been
registered but no data from such trials is available at present.
5. The study in ‘Studies awaiting classification’ may alter the
conclusions of the review once assessed.
Implications for research
A combination of small numbers, different outcome measures and
short duration reduce the strength of most of these trials and the
results need to be confirmed in larger trials.
The early single lesion of DLE may respond well to potent steroid
creams. One of the goals should be to prevent scarring as, once it
occurs, it is largely irreversible.
Well-planned randomised controlled trials are needed to provide
a guide to the treatment of discoid lupus erythematosus. Trials
should not mix different types of lupus together and ideally the
diagnosis should be confirmed with a skin biopsy. There is a need
for trials comparing topical steroids with other agents. The out-
come measures should be stated clearly and should include partic-
ipants’ views and information about scarring. If the CLASI scor-
ing system is adopted widely, more consistent outcome measures
may be obtained. If future trials were to include a core set of out-
come measures, following the recent COUSIN initiative from the
Cochrane Skin Group, there is a much greater likelihood of being
able to pool results from multiple studies in future updates of this
review.
Also, the trials should be of sufficient duration to allow for sea-
sonal variation and capture of relapses (suggested minimum of 9
months). Recurrence rate on and off treatment and occurrence of
side-effects should be documented. Priorities for further studies,
involving larger numbers, are as follows.
1. Potent topical steroid versus chloroquine or
hydroxychloroquine (these antimalarials are cheap and widely
available in many countries).
2. Potent topical steroid versus oral retinoid (more expensive
and can cause birth defects).
3. Potent topical steroid versus methotrexate (cheap and
available but possible liver and bone marrow toxicity, so needs
careful monitoring).
4. Potent topical steroid versus lenalidomide (similar to
thalidomide, but possibly with a better safety profile).
5. Potent topical steroids or chloroquine versus biological
agents.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Barikbin 2009
Methods RCT, 8 weeks of treatment, with further 8-week follow-up.
Participants 10 adults with facial DLE; diagnosis clinical and histological
Interventions Pimecrolimus 1% vs betamethasone 17-valerate 0.1% cream, twice daily
Outcomes Digital photographs; clinical assessment by 3 blinded dermatologists, using a clinical
score*
Notes * Reported erythema and adverse events. Did not report complete resolution or partici-
pant satisfaction
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “all patientswith oddnumberswere
allocated to group A (pimecrolimus 1%)
and all patientswith evennumbers to group
B (betamethasone valerate 0.1%”
Allocation concealment (selection bias) Low risk All patients referred were randomised into
the study. As referrals were from multiple
sources it would not have been possible for
allocations to be knownwhen patients were
referred
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Test products in identical jars.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Clearly stated - outcome assessment was
blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome data was reported for all partic-
ipants, using a combined score, including
erythema
Selective reporting (reporting bias) Low risk None apparent.
Other bias Unclear risk None apparent.
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Barikbin 2009 (Continued)
Comparability of the two arms Low risk Activity scores were similar at baseline: ’4.
2 +/- 0.9’ pimecrolimus vs ’4.4 +/- 2.6’ be-
tamethasone
Jemec 2009
Methods RCT, 8 weeks.
Participants 37 adults with DLE, clinically and histologically.
Interventions R-salbutamol 0.5% topical cream vs placebo, applied twice daily
Outcomes CLASI score; clinician global assessment; participant global assessment, adverse events*
Notes * Reported complete resolution, but not relapse rate or 50% clearing of erythema
Two authors receive support from Astion Pharma A S.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk RCT, using random number chart.
Allocation concealment (selection bias) Unclear risk “The randomisation list consisted of randomisation numbers 1-
64 and uniquely assigned each patient to one of the two treat-
ments”. It was not clear whether this list was kept hidden from
investigators who were responsible for recruitment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Assessors and participants were blinded; creams appeared iden-
tical
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors and participants were blinded; creams appeared iden-
tical
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intent-to-treat analysis was carried out on all patients ran-
domised, with last observation carried forward for any missing
values
Selective reporting (reporting bias) High risk Impact on erythema: no detail supplied.
Other bias Unclear risk Short duration (6 weeks).
Comparability of the two arms Low risk At baseline, the groups were similar according to score. All par-
ticipants had an active lesion
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Kuhn 2011
Methods Within-patient RCT, 12 weeks; diagnosis clinical and histological
Participants 30 adults with cutaneous LE; 14 of them with DLE (subgroup analysis)
Interventions Tacrolimus 0.1% cream vs placebo (vehicle).
Outcomes Digital photography; clinical score; participant satisfaction, adverse events*
Notes * Did not report complete resolution, relapse rate.
Astellas Pharma GmbII assisted with protocol design.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated.
Allocation concealment (selection bias) Low risk Allocation by pharmacy independent of
the investigators. Quote “patients were ran-
domly assigned to either 0.1% tacrolimus
ointment or the placebo (vehicle) by the
pharmacy at each center”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Containers identical.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Patients and physicians were blinded dur-
ing the trial”.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 of the 14 participants with DLE did not
complete the trial. Intention to treat anal-
ysis was used in a secondary analysis
Selective reporting (reporting bias) Unclear risk Not apparent.
Other bias Unclear risk None apparent.
Comparability of the two arms Low risk Matched skin lesions used in individual
participants.
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Roenigk 1980
Methods RCT, cross-over at 6 weeks, duration 12 weeks. Data was analysed at 6 weeks as a parallel
trial; data after the cross-over component was excluded
Participants 78 adults, clinical diagnosis DLE well-matched.
Interventions Fluocinonide cream 0.05% vs hydrocortisone cream 1% given 3 times daily without
occlusion
Outcomes Skin cleared or much improved - the lowest score of 1 if the lesion was worse, the highest
score 5 if the lesion was excellent or clear*
Notes *Did report resolution and adverse events, not % change in erythema, relapse rate or
participant satisfaction
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomly assigned... ” “Sta-
tistical tests of equality ..showed successful
randomisation”
Allocation concealment (selection bias) Unclear risk No details about how the allocation se-
quence was concealed from the participants
and clinicians. Creams were provided in
identical base
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as a “double-blind” trial.
“Both medications were supplied in a
specifically formulated cream base...in
identical tubes”. Participants had one active
lesion which was monitored every 3 weeks
- it is not clear if they were aware which
lesion this was
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated, but “double-blind”.
Incomplete outcome data (attrition bias)
All outcomes
High risk 78 of 93 participants were assessed at 6
weeks, 15 of the 93 patients who did not
complete the first phase of the study did so
for reasons which may relate to outcome
Selective reporting (reporting bias) Low risk Not apparent.
Other bias Unclear risk Short duration (6 weeks).
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Roenigk 1980 (Continued)
Comparability of the two arms Low risk The fluocinonide and hydrocortisone
groups were similar at baseline with respect
to sex, age, race, duration of disease and
duration of monitored lesion
Ruzicka 1992
Methods RCT, duration 8 weeks (included DLE and subacute LE).
Participants 58 adults, clinical diagnosis DLE or SCLE, not matched for diagnosis
Interventions Acitretin 50 mg vs hydroxychloroquine 400 mg daily.
Outcomes An ordinal scale used to assess the skin initially and at follow-up visits: Complete clearing
= 0, improvement = 1, no change or deterioration = 2. Clearing of skin lesions and
erythema were assessed*
Notes Reported complete resolution and adverse events, not participant satisfaction or relapse
rate
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “..was conducted in a randomised fashion”
and “patients were randomly assigned” but
no further details
Allocation concealment (selection bias) Unclear risk No details about how the allocation se-
quence was concealed from the participants
and clinicians
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study described as “double-blind” - but no
further details were given
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Stated as double-blind but no details given
as to how outcome assessors were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 out of 60 patients randomised did not
contribute to the analysis. ITT not de-
scribed
Selective reporting (reporting bias) Unclear risk None apparent.
Other bias High risk Clinical heterogeneity.
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Ruzicka 1992 (Continued)
Comparability of the two arms High risk More participants with DLE in hydroxy-
chloroquine group.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Avgerinou 2012 Results for DLE subset not reported; not an RCT.
Bezerra 2005 Trial results included other disorders, outcome in DLE could not be established
Bjornberg 1963 Not randomised trial.
Furie 2015a Participants with SLE, results for DLE subset not reported.
Furie 2015b Participants with SLE, results for DLE subset not reported.
Gammon 2011 Not an RCT.
Islam 2012 Participants with SLE, results for DLE subset not reported.
Khamashta 2016 Participants with SLE, results for DLE subset not reported.
Kraak 1965 Not RCT.
Kuhn 2011a Photoprotection trial, not drug treatment.
Kuhn 2016 Not RCT.
Madan 2010 Not RCT. Results for DLE subset not reported separately.
Manzi 2012 Study of people with SLE. Results for DLE not reported.
Merrill 2010a Study of people with SLE. Results for DLE not reported.
Merrill 2010b Study of people with SLE. Results for DLE not reported
Merrill 2011 Study of people with SLE. Results for DLE not reported.
Ordi-Ros 2000 Not RCT.
Szepietowski 2013 Study of people with SLE. Results for DLE not reported.
Thivolet 1990 Not RCT.
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(Continued)
Tzung 2007 Most participants had malar rash of acute SLE (13 of 18). Results for DLE subset (4 people) could not be
established
Wang 2015 Uncertain diagnosis.
Yokogawa 2015 Included participants with all forms of lupus, results for DLE subset not reported
Zhong 2013 Participants with SLE, results for DLE subset not reported.
Characteristics of studies awaiting assessment [ordered by study ID]
NCT00001680
Methods RCT, two matched lesions in same participant.
Participants 17 adults with DLE.
Interventions Thalidomide 20% ointment under occlusion.
Outcomes Completed.
Notes -
NCT00222183
Methods RCT.
Participants Peope with DLE, all ages.
Interventions Pimecrolimus cream vs betamethasone valerate 0.1% cream.
Outcomes Clinical score, adverse events.
Notes -
NCT00625157
Methods Randomised, double-blind trial.
Participants Adults with DLE.
Interventions ASF cream 0.5% (R-salbutamol) vs placebo.
Outcomes GA, CLASI, QoL.
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NCT00625157 (Continued)
Notes Completed, results not posted.
NCT00625521
Methods RCT, multicentre.
Participants 32 adults with DLE.
Interventions ASF cream vs placebo.
Outcomes Safety, CLASI, Global assessment by participant and investigator
Notes Completed 2007.
NCT01164917
Methods RCT, cross-over study.
Participants 16 adults with DLE.
Interventions AMG811 (interferon gamma blocker) injection vs placebo.
Outcomes Safety; secondary outcome is CLASI score changes.
Notes Passed completion date.
NCT01300208
Methods Randomised, double-blind study.
Participants People with DLE and SCLE.
Interventions CC 11050 (Celgene).
Outcomes Adverse effects, pharmacokinetics, CLASI.
Notes -
NCT01407679
Methods Randomised, double-blind.
Participants 7 adults with cutaneous lupus.
Interventions Alitretinoin (Toctino®) vs placebo.
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NCT01407679 (Continued)
Outcomes CLASI, percentage with improvement by global assessment, adverse events
Notes -
NCT01597050
Methods Randomised, double-blind trial.
Participants 54 adults with DLE.
Interventions R932333 6% cream vs placebo.
Outcomes Erythema and scaling score.
Notes Trial discontinued. Results not published.
Pothinamthong 2012
Methods Randomised, to right or left side of the body, for 6 weeks.
Participants 21 Thai adults with DLE.
Interventions Tacrolimus 0.1% cream vs clobetasol propionate 0.05%.
Outcomes CLASI score.
Notes Information from abstract only. We were unable to obtain full text
Characteristics of ongoing studies [ordered by study ID]
NCT02927457
Trial name or title A Double-blind (Sponsor Unblinded) Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmaco-
dynamics and Clinical Effect of Repeat Dosing of GSK2646264 in Cutaneous Lupus Erythematosus Patients
Methods Randomised, double-blind trial.
Participants 40 people with cutaneous LE.
Interventions GSK2646264 1% cream vs placebo.
Outcomes Adverse effects, CLASI, pharmacokinetics.
Starting date January 2017.
41Drugs for discoid lupus erythematosus (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT02927457 (Continued)
Contact information US GSK Clinical Trials Call Center
877-379-3718
GSKClinicalSupportHD@gsk.com
Notes -
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D A T A A N D A N A L Y S E S
Comparison 1. Fluocinonide versus hydrocortisone cream
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Resolution of skin lesions 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 2. Acitretin versus hydroxychloroquine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Resolution of skin lesions 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Clearing of erythema 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Fluocinonide versus hydrocortisone cream, Outcome 1 Resolution of skin
lesions.
Review: Drugs for discoid lupus erythematosus
Comparison: 1 Fluocinonide versus hydrocortisone cream
Outcome: 1 Resolution of skin lesions
Study or subgroup fluocinonide hydrocortisone Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Roenigk 1980 10/37 4/41 2.77 [ 0.95, 8.08 ]
0.1 0.2 0.5 1 2 5 10
Favours hydrocort Favours fluocinon
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Analysis 2.1. Comparison 2 Acitretin versus hydroxychloroquine, Outcome 1 Resolution of skin lesions.
Review: Drugs for discoid lupus erythematosus
Comparison: 2 Acitretin versus hydroxychloroquine
Outcome: 1 Resolution of skin lesions
Study or subgroup acitretin hydroxychloroquine Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ruzicka 1992 13/28 15/30 0.93 [ 0.54, 1.59 ]
0.1 0.2 0.5 1 2 5 10
Favours hydroxychl Favours acitretin
Analysis 2.2. Comparison 2 Acitretin versus hydroxychloroquine, Outcome 2 Clearing of erythema.
Review: Drugs for discoid lupus erythematosus
Comparison: 2 Acitretin versus hydroxychloroquine
Outcome: 2 Clearing of erythema
Study or subgroup acitretin hydroxychloroquine Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ruzicka 1992 10/24 17/25 0.61 [ 0.36, 1.06 ]
0.01 0.1 1 10 100
Favours hydroxchl Favours acitretin
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A P P E N D I C E S
Appendix 1. CENTRAL (Cochrane Library) search strategy
#1 discoid lupus erythematosus
#2 (cutaneous or skin) and lupus erythematosus
#3 MeSH descriptor: [Lupus Erythematosus, Cutaneous] explode all trees
#4 MeSH descriptor: [Lupus Erythematosus, Discoid] explode all trees
#5 #1 or #2 or #3 or #4
Appendix 2. MEDLINE (Ovid) search strategy
1. discoid lupus erythematosus.mp.
2. Lupus Erythematosus, Cutaneous/
3. cutaneous lupus.mp.
4. Lupus Erythematosus, Discoid/
5. or/1-4
6. randomised controlled trial.pt.
7. controlled clinical trial.pt.
8. randomized.ab.
9. placebo.ab.
10. clinical trials as topic.sh.
11. randomly.ab.
12. trial.ti.
13. 6 or 7 or 8 or 9 or 10 or 11 or 12
14. exp animals/ not humans.sh.
15. 13 not 14
16. 5 and 15
[Lines 6-15: Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity- and precision-
maximizing version (2008 revision)]
Appendix 3. Embase (Ovid) search strategy
1. discoid lupus erythematosus/
2. discoid lupus erythematosus.mp.
3. skin lupus erythematosus/
4. cutaneous lupus erythematosus.mp.
5. or/1-4
6. crossover procedure.sh.
7. double-blind procedure.sh.
8. single-blind procedure.sh.
9. (crossover$ or cross over$).tw.
10. placebo$.tw.
11. (double$ adj blind$).tw.
12. allocat$.tw.
13. trial.ti.
14. randomised controlled trial.sh.
15. random$.tw.
16. or/6-15
17. exp animal/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
18. human/ or normal human/
19. 17 and 18
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20. 17 not 19
21. 16 not 20
22. 5 and 21
Appendix 4. LILACS search strategy
(discoid$ and lupus and (erythematosus or eritematoso))
These terms combined with the Controlled clinical trials topic-specific query filter.
WH A T ’ S N E W
Date Event Description
22 September 2016 New search has been performed We added three new studies and updated the review
according to MECIR
22 September 2016 New citation required but conclusions have not
changed
The three new studies did not address any of the re-
view’s primary outcomes
H I S T O R Y
Date Event Description
6 August 2009 New citation required but conclusions have not
changed
Change to authors
11 June 2009 New search has been performed Further search carried out, no new studies found
28 November 2008 Amended New search completed, no studies found
1 November 2008 Amended Converted to new review format
2 January 2008 Amended New studies found and included or excluded
2 January 2008 Amended Conclusions changed
1 January 2008 New citation required and conclusions have changed Substantive amendment
3 September 2003 Amended New studies sought but none found
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Differences between the protocol and the current update
For differences between other published versions, please see the ’Differences between protocol and review section’ within the original
publications.
Note: many of the methods section headings are missing from the protocol and previously published versions. In this update, we have
tried to rectify this, in line with the current Cochrane Handbook and RevMan software.
Background: this section has been updated.
Objectives: the sentence ’To identify the need for further study to make rational clinical decisions possible when treating cutaneous
lupus’ was omitted from this update in line with current Cochrane Handbook for Systematic Reviews of Interventions and RevMan 5
software and the previously published versions of the review as it was considered redundant.
Types of interventions: we planned to include other anti-malarial quinines other than chloroquine and hydroxychloroquine, but did not
find any RCTs for these interventions. Although not planned in the protocol, in this update we did additionally include lenalidomide,
biological agents, (including abatacept, adalimumab, belimumab, etanercept, efalizumab, infliximab, rituximab, sifalimumab and
sirukumab), topical calcineurin antagonists, (tacrolimus and pimecrolimus) and topical salbutamol as these agents had become available
and trials had been performed in connective tissue disorders. We also clarified the types of comparators we would accept, as this detail
was not specified in the protocol. We expanded the list of excluded interventions to include phototherapy and photoprotection, which
were not originally listed in the protocol, for clarification only. This does not represent a change in methodology.
Types of outcome measures: in a previous version of the review, under Primary outcomes, we added ’percentage of people with’ to
our ’complete resolution of skin lesions…’ and ’clearing of erythema…’ outcomes, and these have been retained (Jessop 2009). Note
that we accepted the following terms to describe complete resolution: complete clearing, clearing, marked improvement and excellent
improvement.
Searching other resource: although not planned in the protocol, we searched Index Medicus by hand for studies relating to treatment
of discoid lupus erythematosus for the years 1956 to 1966 because we thought it important, and we recorded all adverse events reported
in the included and excluded studies as we recognise the need to report adverse events.
Search methods for identification of studies: the databases and date ranges that we planned to search in the protocol have been
extended for this update review, in line with current standard search methods.
Data collection and analysis: In the original protocol, we had not made plans at all regarding how to deal with within-patient studies,
missing data, sensitivity analysis, and ’Summary of findings’ tables, but we now have in line with current requirements.
Where results are estimated for individual studies with low numbers of outcomes (< 10 in total) or where the total sample size is less
than 30 participants, we decided to report the proportion of outcomes in each treatment group together with a P value from a Fisher’s
Exact test. This follows guidance provided by the Skin Group Statistics editors on how to deal with small numbers, made available
since the last update of this review.
“We tested statistical heterogeneity using the I² statistic (0% to 40%: may not be important; 30% to 60%: may represent moderate
heterogeneity; 50% to 90%: may represent substantial heterogeneity; 75% to 100%: represents considerable heterogeneity) (Higgins
2011).” An assessment of how we would deal with heterogeneity was missing from the original protocol therefore we have amended
this at this stage in the event that future updates of this review will contain a pooled analysis of two or more studies.
Assessment of risk of bias in included studies: the text within this section was written in the ’Quality rating of included studies’
section of the protocol. The review has been amended to follow the RevMan 5 recommended headings and the newCochrane Handbook
for Systematic Reviews of Interventions guidelines.
Two additional headings have been added to this section: Comparability of the two arms and Intention to treat analysis.
According to the Cochrane Handbook for Systematic Reviews of Interventions, controlled trials that allocate participants by quasi-ran-
domisation, or that fail to conceal allocation during recruitment, are at risk of selection bias. We have included such trials, but have
indicated that there is high risk of selection bias.
Imbalance at baseline has been assessed in this version of the review and added to the risk of bias tables.
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Measures of treatment effect: although not planned in the protocol, for any significant outcomes (P < 0.05) we wanted to present the
number needed to treat for an additional harmful outcome (NNTH) where the first treatment in the comparison is harmful (risk ratio
(RR) > 1 for safety outcomes). We did not do this as no significant harms were reported.
In the protocol, we did not pre-state the effect measures that we would report. For dichotomous outcomes (primary outcomes 1 and 2
and adverse events), results are presented as RR with 95% confidence intervals (CI). For this update, for continuous outcomes (primary
outcome 3), we planned to present results in the form of mean differences (with 95% CIs). Where there were treatment comparisons
where studies used different scales for the same outcome, we planned to convert results to standard mean differences (SMD) to allow
pooling of results. We could not carry out these plans because the studies were few and heterogeneous.
Unit of analysis issues > Cross-over trials: in the protocol we did not plan how to analyse cross-over trials; but having included such
a study, we followed the guidance provided in Section 16.4.4 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011).Where no evidence of a carry-over effect was present, analyses of paired differences were presented if these data could be obtained
from the trial report. Otherwise, only data from the first treatment period were used.
Unit of analysis issues >Within-patient studies: although not planned in the protocol, internally controlled trials were analysed using
techniques for paired designs (e.g. paired t-test, McNemar’s test). Where appropriate, these were included in additional data tables and
not pooled with parallel group trials.
Assessment of heterogeneity: in the protocol, we had planned to use statistical tests for homogeneity between studies. However,
assessment of heterogeneity was not performed as no findings were based on pooled results from 2 or more trials.
Data synthesis: in the protocol, we planned to draw up a synthesis of included trials; however, this was not possible with the data in
the studies we found, due to heterogeneity of study methods and interventions. No two trials investigated the same interventions.
Subgroup analysis and investigation of heterogeneity: in the protocol, we had planned to perform subgroup analysis on the following
measures: disseminated DLE versus localised DLE; DLE with systemic lupus versus DLE without systemic lupus; histologically proven
versus clinically diagnosed DLE; and effect of ethnic group on outcome. However, we were unable to address these issues, as none of
the studies provided data on individual subgroups, (and two of the trials enrolled small numbers of participants).
Trials that included more than one subset of cutaneous lupus were included if most participants had DLE and the outcome data
described outcomes for DLE.
Other: we planned where possible to calculate cost effectiveness ratios using quality-of life-measures; however, the studies identified
did not provide these data.
’Summary of findings’ table: although not planned in the protocol, we used GRADEpro 2008 to create a ’Summary of findings’ table
as suggested in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). In this, we have summarised the primary
outcomes for the most important comparisons. Subgroup analysis was not possible.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Acitretin [therapeutic use]; Dermatologic Agents [∗therapeutic use]; Fluocinonide [therapeutic use]; Hydrocortisone [therapeutic use];
Hydroxychloroquine [therapeutic use]; Lupus Erythematosus, Discoid [∗drug therapy]; Randomized Controlled Trials as Topic
MeSH check words
Humans
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